Seizure Treatment Protocol: Anti-Seizure Drugs; Lorazepam, Diazepam, Midazolam, Fosphenytoin, Phenytoin, Levetiracetam, Valproate, Phenobarbital, Propofol, Pentobarbital, Thiopental, and Ketamine.
A table with fixed doses for adults in an easy-to-use format, ready for ordering medications during the management of seizures, specifically status epilepticus (SE).
| Phase | Drug | Adult Fixed Dose | Administration Route | Max Dose (Adults) |
|---|---|---|---|---|
| Early SE (First 10 minutes) | Lorazepam (LZP) | 4 mg | IV (can repeat in 5-10 min) | 4 mg |
| Diazepam (DZP) | 10 mg | IV or Rectal | 10 mg (IV) or 20 mg (rectal) | |
| Midazolam (MDZ) | 10 mg | IM, IN, IV, Buccal, Rectal | 10 mg | |
| Midazolam (Buccal) | 10 mg | Buccal | 10 mg | |
| Midazolam (Rectal) | 10 mg | Rectal | 10 mg | |
| Diazepam (Rectal) | 20 mg | Rectal | 20 mg | |
| Established SE (10-30 minutes) | Fosphenytoin (FosPHT) | 1500 mg PE | IV (rate up to 150 mgPE/min) | 1500 mg PE |
| Phenytoin (PHT) | 1500 mg | IV (rate up to 50 mg/min) | 1500 mg | |
| Levetiracetam (LEV) | 3000-4500 mg | IV | 4500 mg | |
| Valproate (VPA) | 3000 mg | IV | 3000 mg | |
| Phenobarbital (PHB) | 1000 mg | IV (rate 30-60 mg/min) | 1000 mg | |
| Refractory SE (>30 minutes) | Midazolam | Loading: 10 mg, then 0.05-2 mg/kg/h | IV (continuous infusion) | N/A |
| Propofol | Loading: 1-2 mg/kg, followed by 2-12 mg/kg/h | IV (continuous infusion) | N/A | |
| Pentobarbital | Loading: 5-15 mg/kg, followed by 0.5-5 mg/kg/h | IV (continuous infusion) | N/A | |
| Thiopental | Loading: 2-7 mg/kg, followed by 0.5-5 mg/kg/h | IV (continuous infusion) | N/A | |
| Ketamine | Loading: 100 mg, followed by 2-7.5 mg/kg/h | IV (continuous infusion) | N/A |
Key Notes:
- Lorazepam (LZP): 4 mg IV is preferred as a single fixed dose for adults, repeat once if needed.
- Diazepam (DZP): 10 mg IV or rectal is the fixed dose, can be repeated in refractory cases.
- Midazolam (MDZ): 10 mg is used for various routes including IM, IN, Buccal, or Rectal.
- Fosphenytoin (FosPHT): 1500 mg PE is administered as a fixed dose intravenously for established SE.
- Levetiracetam (LEV): Doses between 3000 mg and 4500 mg are effective for seizure control.
- Valproate (VPA): A single dose of 3000 mg IV is the maximum dose for established SE.
- Refractory SE agents (e.g., Midazolam, Propofol, Pentobarbital) require loading doses followed by continuous infusions tailored to the patient's needs.
This table recaps the step-by-step approach to ordering drugs for the treatment of seizures, particularly status epilepticus (SE), with differentiation between adult and pediatric dosing. It includes the phases of early, established, and refractory status epilepticus and outlines maximum dosages and administration routes.
| Phase | Drug | Dose (Adults) | Dose (Pediatrics) | Administration Route | Max Dose (Adults) | Max Dose (Pediatrics) |
|---|---|---|---|---|---|---|
| Early SE (First 10 minutes) | Lorazepam (LZP) | 0.1 mg/kg | 0.05-0.1 mg/kg | IV | 4 mg | 4 mg |
| Diazepam (DZP) | 0.15-0.2 mg/kg | 0.15-0.2 mg/kg | IV or Rectal | 10 mg (IV) or 20 mg (rectal) | 10 mg (IV) or 20 mg (rectal) | |
| Midazolam (MDZ) | 0.2 mg/kg (IM/IN) or 0.15 mg/kg (IV) | 0.2 mg/kg (IM/IN) or 0.15 mg/kg (IV) | IM, IN, IV, Buccal, Rectal | 10 mg | 10 mg | |
| Midazolam (Buccal) | 10 mg | 10 mg | Buccal | 10 mg | 10 mg | |
| Midazolam (Rectal) | 0.3 mg/kg | 0.3 mg/kg | Rectal | 10 mg | 10 mg | |
| Diazepam (Rectal) | 0.2-0.5 mg/kg | 0.5 mg/kg | Rectal | 20 mg | 20 mg | |
| Established SE (10-30 minutes) | Fosphenytoin (FosPHT) | 20 mgPE/kg | 20 mgPE/kg | IV (rate up to 150 mgPE/min) | 1500 mg PE | 1500 mg PE |
| Phenytoin (PHT) | 20 mg/kg | 20 mg/kg | IV (rate up to 50 mg/min) | 1500 mg | 1500 mg | |
| Levetiracetam (LEV) | 30-60 mg/kg | 20-60 mg/kg | IV | 4500 mg | 3000 mg | |
| Valproate (VPA) | 20-40 mg/kg | 20-40 mg/kg | IV | 3000 mg | 3000 mg | |
| Phenobarbital (PHB) | 20 mg/kg | 20 mg/kg | IV (rate 30-60 mg/min) | 1000 mg | 1000 mg | |
| Refractory SE (>30 minutes) | Midazolam | Loading: 0.2 mg/kg, followed by 0.05-2 mg/kg/h | Loading: 0.2 mg/kg, followed by 0.05-2 mg/kg/h | IV (continuous infusion) | N/A | N/A |
| Propofol | Loading: 1-2 mg/kg, followed by 2-12 mg/kg/h | Loading: 1-2 mg/kg, followed by 2-12 mg/kg/h | IV (continuous infusion) | N/A | N/A | |
| Pentobarbital | Loading: 5-15 mg/kg, followed by 0.5-5 mg/kg/h | Loading: 5-15 mg/kg, followed by 0.5-5 mg/kg/h | IV (continuous infusion) | N/A | N/A | |
| Thiopental | Loading: 2-7 mg/kg, followed by 0.5-5 mg/kg/h | Loading: 2-7 mg/kg, followed by 0.5-5 mg/kg/h | IV (continuous infusion) | N/A | N/A | |
| Ketamine | Loading: 1.5-4.5 mg/kg, followed by 2-7.5 mg/kg/h | Loading: 1.5-4.5 mg/kg, followed by 2-7.5 mg/kg/h | IV (continuous infusion) | N/A | N/A |
Key Points:
- Maximum doses for adults are usually based on total mg per dose or kg body weight (e.g., lorazepam: max 4 mg IV).
- Pediatric doses are calculated on a mg/kg basis and are typically lower than adult maximums.
- The choice of medication depends on patient response and available routes of administration.
- Refractory SE often requires ICU admission with continuous EEG monitoring, and sedation is adjusted based on the patient's clinical status.
Seizures, particularly status epilepticus (SE), represent a critical neurological emergency that requires immediate and precise management. SE is defined as a seizure lasting more than five minutes or recurrent seizures without full recovery between episodes. The management of SE involves rapid administration of antiepileptic drugs (AEDs) to terminate seizures and prevent recurrence. This article provides a comprehensive, step-by-step approach to managing seizures, tailored for residents, with an emphasis on understanding the pharmacokinetics, dosing, and clinical application of various AEDs.
Introduction
Status epilepticus is a life-threatening condition that can lead to significant morbidity and mortality if not promptly treated. The primary goals in managing SE are to stop ongoing seizures and prevent further episodes while minimizing complications. This requires a thorough understanding of the pharmacological agents used, their dosages, routes of administration, and potential side effects.
Step 1: Initial Management in Early Status Epilepticus (First 10 minutes)
In the first few minutes of a seizure, the goal is to terminate the seizure activity quickly using fast-acting benzodiazepines. Benzodiazepines enhance the effect of the neurotransmitter GABA at the GABA-A receptor, leading to increased neuronal inhibition and rapid seizure termination.
For Adults:
- IV Lorazepam (LZP): Administer 0.1 mg/kg intravenously, with a maximum dose of 4 mg. Lorazepam is preferred due to its longer duration of action in the central nervous system (CNS), which provides more sustained seizure control. Repeat the dose once if the seizure persists after 5-10 minutes.
- IV Diazepam (DZP): Administer 0.15-0.2 mg/kg intravenously, with a maximum dose of 10 mg. Diazepam is highly lipid-soluble, leading to a rapid onset of action but a shorter duration of effect due to redistribution into peripheral tissues. It can also be administered rectally (0.2-0.5 mg/kg, maximum 20 mg) if IV access is not available.
- IV/IM/IN Midazolam (MDZ): Administer 0.2 mg/kg intramuscularly or intranasally, or 0.15 mg/kg intravenously, with a maximum dose of 10 mg. Midazolam has a very rapid onset due to its water solubility, making it ideal for intramuscular or intranasal administration when IV access is not readily available. Buccal administration (10 mg) or rectal administration (0.3 mg/kg) are alternative routes.
For Pediatrics:
- Lorazepam: 0.05-0.1 mg/kg IV, with a maximum dose of 4 mg.
- Diazepam: 0.15-0.2 mg/kg IV, with a maximum dose of 10 mg. Rectal administration can also be used at a dose of 0.5 mg/kg (maximum 20 mg).
- Midazolam: 0.2 mg/kg IM/IN, 0.15 mg/kg IV, or 0.3 mg/kg rectally, with a maximum dose of 10 mg.
These initial treatments are designed to rapidly control seizures, providing time for further diagnostic and therapeutic measures.
Step 2: Management in Established Status Epilepticus (10-30 minutes)
If seizures persist after initial benzodiazepine administration, additional AEDs are administered to provide sustained seizure control. The choice of AED depends on various factors, including drug availability, patient history, and underlying conditions.
For Adults:
- IV Fosphenytoin (FosPHT): Administer 20 mg phenytoin equivalents (PE)/kg intravenously, with a maximum dose of 1500 mg PE. Fosphenytoin is a prodrug of phenytoin and is preferred due to its lower risk of causing cardiovascular side effects like hypotension and arrhythmias. It can be administered at a faster rate (up to 150 mg PE/min) compared to phenytoin.
- IV Phenytoin (PHT): Administer 20 mg/kg intravenously, with a maximum dose of 1500 mg. Phenytoin is a sodium channel blocker that stabilizes neuronal membranes and is effective for seizure control. However, it requires slower administration (maximum 50 mg/min) to reduce the risk of hypotension and arrhythmias.
- IV Levetiracetam (LEV): Administer 30-60 mg/kg intravenously, with a maximum dose of 4500 mg. Levetiracetam has a favorable safety profile, with minimal drug interactions and no need for routine serum level monitoring. It is often used due to its ease of use and lack of sedation or respiratory depression.
- IV Valproate (VPA): Administer 20-40 mg/kg intravenously, with a maximum dose of 3000 mg. Valproate increases GABA levels and has broad-spectrum efficacy against different seizure types. It is contraindicated in patients with liver disease or certain mitochondrial disorders.
- IV Phenobarbital (PHB): Administer 20 mg/kg intravenously, with a maximum dose of 1000 mg. Phenobarbital enhances GABA activity and is often reserved for refractory cases due to its sedative effects and potential for respiratory depression.
For Pediatrics:
- Fosphenytoin: 20 mg PE/kg IV, maximum dose 1500 mg PE. Rate of administration up to 150 mg PE/min.
- Phenytoin: 20 mg/kg IV, maximum dose 1500 mg. Rate of administration up to 50 mg/min.
- Levetiracetam: 20-60 mg/kg IV, maximum dose 3000 mg.
- Valproate: 20-40 mg/kg IV, maximum dose 3000 mg.
- Phenobarbital: 20 mg/kg IV, maximum dose 1000 mg.
During this phase, careful monitoring of cardiac function and respiratory status is crucial, especially in pediatric patients, who may have a lower threshold for adverse effects.
Step 3: Management in Refractory Status Epilepticus (>30 minutes)
Refractory status epilepticus (RSE) is defined as persistent seizure activity despite the use of adequate doses of two antiepileptic drugs, including a benzodiazepine. RSE requires more aggressive management, often involving anesthetic agents and ICU admission.
For Adults and Pediatrics:
- IV Midazolam: Administer a loading dose of 0.2 mg/kg followed by a continuous infusion of 0.05-2 mg/kg/h. Midazolam is favored for its rapid onset and short duration of action, which allows for quick titration.
- IV Propofol: Administer a loading dose of 1-2 mg/kg followed by a continuous infusion of 2-12 mg/kg/h. Propofol is effective for inducing burst suppression on EEG, which is often the goal in treating RSE. It requires careful monitoring due to the risk of hypotension and propofol infusion syndrome.
- IV Pentobarbital: Administer a loading dose of 5-15 mg/kg followed by a continuous infusion of 0.5-5 mg/kg/h. Pentobarbital is a barbiturate that induces deep sedation and burst suppression but has a higher risk of hypotension and respiratory depression, necessitating mechanical ventilation.
- IV Thiopental: Administer a loading dose of 2-7 mg/kg followed by a continuous infusion of 0.5-5 mg/kg/h. Thiopental, similar to pentobarbital, is used to achieve deep sedation but is less commonly used due to its prolonged effects.
- IV Ketamine: Administer a loading dose of 1.5-4.5 mg/kg followed by a continuous infusion of 2-7.5 mg/kg/h. Ketamine, an NMDA receptor antagonist, may be used for its neuroprotective effects and minimal impact on respiratory drive.
These treatments aim to achieve EEG burst suppression or cessation of electrographic seizure activity to protect against further neuronal injury.
Step 4: Follow-Up and Monitoring
After seizure control is achieved, ongoing monitoring and management are essential to prevent recurrence and manage potential complications.
- Continuous EEG monitoring: For patients with RSE, continuous EEG is critical to assess for ongoing seizure activity, especially in patients who are sedated and cannot be assessed clinically.
- Frequent reassessment of vital signs: Close monitoring of respiratory and cardiovascular function is necessary, particularly in patients receiving sedative infusions or those with underlying cardiac or respiratory conditions.
- Monitoring of drug levels: For drugs like phenytoin, monitoring serum levels can help ensure therapeutic levels are achieved without reaching toxic levels. This is especially important in patients with altered pharmacokinetics, such as those with renal or hepatic impairment.
- Laboratory monitoring: Regular assessment of renal and hepatic function, as well as blood counts and electrolytes, is crucial to detect any drug-related toxicity or complications of prolonged seizures.
Pharmacokinetics and Clinical Considerations
A detailed understanding of the pharmacokinetics of each antiepileptic drug is essential for optimizing therapy:
- Diazepam: Highly lipid-soluble, diazepam quickly crosses the blood-brain barrier, providing rapid seizure control. However, its high lipid solubility also leads to rapid redistribution into fatty tissues, resulting in a short duration of action in the CNS. This necessitates repeated dosing or the use of adjunctive long-acting agents.
- Lorazepam: Less lipid-soluble than diazepam, lorazepam has a slower onset but a longer duration of action in the CNS. This makes it ideal for sustained seizure control after initial stabilization.
- Midazolam: Water-soluble and with a very short half-life, midazolam is quickly metabolized, making it suitable for continuous infusion in a controlled environment like the ICU. Its rapid onset and short duration allow for quick titration, which is beneficial in managing refractory seizures.
- Phenytoin and Fosphenytoin: Phenytoin is a sodium channel blocker with a narrow therapeutic index, requiring careful monitoring of serum levels to avoid toxicity. Fosphenytoin, a prodrug of phenytoin, is less irritating to veins and can be infused more rapidly, making it preferable for initial management of status epilepticus.
- Levetiracetam: With minimal drug interactions and no need for serum level monitoring, levetiracetam is increasingly used in various seizure types, including SE. Its mechanism of action is not entirely understood but involves binding to the synaptic vesicle protein SV2A, which may modulate neurotransmitter release.
- Valproate: Valproate has broad-spectrum activity against various seizure types and works by increasing GABA levels in the brain. It is contraindicated in patients with liver disease and certain metabolic disorders, and its use requires monitoring for hepatotoxicity and hyperammonemia.
- Phenobarbital: A long-acting barbiturate, phenobarbital is effective for refractory seizures but is sedating and can depress respiration, necessitating careful use in monitored settings.
Conclusion
The management of seizures, particularly status epilepticus, requires a thorough understanding of the pharmacological agents available, their appropriate dosages for adults and pediatric patients, and the correct administration routes. Initial treatment with benzodiazepines is crucial for rapid seizure control, followed by additional AEDs if seizures persist. In cases of refractory status epilepticus, ICU-level care and continuous EEG monitoring are essential to ensure adequate control and minimize complications.
By mastering these steps and understanding the pharmacokinetics and clinical applications of various AEDs, residents can effectively manage seizures, reduce the risk of long-term neurological damage, and improve patient outcomes in both adult and pediatric populations.